Primary Hyperparathyroidism: How Calcium and PTH Establish the Pattern

Primary hyperparathyroidism is not diagnosed from a high calcium result alone or from a high parathyroid hormone result alone. The defining evidence is the relationship between them. When calcium rises, a healthy feedback system should suppress parathyroid hormone, usually shortened to PTH. A PTH value that remains elevated, or merely stays within the laboratory reference interval when it should be low, is therefore inappropriate for the calcium level and points toward primary hyperparathyroidism.

The Fifth International Workshop recommends confirming hypercalcemic primary hyperparathyroidism with elevated albumin-adjusted serum calcium and elevated or inappropriately normal intact PTH on two occasions, at least two weeks apart. That repeated pattern matters because hydration, albumin, medicines, assay effects, and acute illness can all distort a single result.

Start with the feedback loop#

The parathyroid glands help keep extracellular calcium within a narrow range. When calcium falls, PTH rises. It increases renal calcium retention, promotes phosphate loss in urine, supports production of active vitamin D, and increases calcium movement from bone when needed. When calcium rises, PTH should fall.

That physiology explains why the laboratory reference interval cannot be read in isolation. Suppose calcium is repeatedly above its upper reference limit and PTH sits near the middle of its stated normal range. That PTH should not reassure you. It has failed to suppress in the setting that should switch it off. By contrast, clearly suppressed PTH redirects the differential toward causes outside the parathyroid glands, such as malignancy-related pathways, vitamin D excess, granulomatous disease, thyrotoxicosis, or other less common conditions.

The key first reconstruction is therefore simple:

1. Was calcium truly high and was it repeated?
2. Were calcium and PTH interpreted from appropriately timed samples?
3. Is PTH suppressed, appropriately low, or inappropriately preserved?
4. Could a medicine, assay problem, kidney disorder, or inherited calcium-sensing difference explain the pattern?

Confirm that calcium is truly elevated#

Total serum calcium includes calcium bound to albumin, so a low or high albumin concentration can make total calcium look lower or higher without an equivalent change in the biologically active ionized fraction. Albumin-adjustment formulas are commonly used, but they are estimates and can perform poorly in some clinical settings. Direct ionized calcium measurement can resolve uncertainty when total calcium and the clinical context disagree.

Pre-analytic conditions also matter. Dehydration may transiently concentrate serum constituents. A prolonged tourniquet, sampling conditions, or an acute change in kidney function can complicate interpretation. The most persuasive evidence is a stable pattern across repeat measurements, supported by albumin and kidney function data rather than the one flag you noticed on a chemistry panel.

Assay interference belongs on the checklist when results do not make physiological sense. High-dose biotin supplements can interfere with some immunoassays, although the direction and magnitude depend on the platform. The useful response to a discordant result is not to force it into a diagnosis, but to clarify the collection conditions, repeat the measurement, and call the laboratory when you need to.

Hypercalcemic and normocalcemic disease are different diagnostic routes#

Classic primary hyperparathyroidism has elevated calcium with elevated or inappropriately normal PTH. Normocalcemic primary hyperparathyroidism is narrower and harder to establish. The Fifth Workshop defines it through normal albumin-adjusted total calcium and normal ionized calcium with elevated intact PTH on at least two occasions over three to six months, after excluding alternative causes of secondary hyperparathyroidism.

That last clause does most of the work. PTH can rise appropriately when the body is defending calcium balance. Important secondary explanations include vitamin D deficiency, chronic kidney disease, low calcium intake, malabsorption, and medicines that alter bone or calcium metabolism. Antiresorptive drugs can raise PTH, as can some other therapies. Hypercalciuria may also stimulate a secondary response in some patients.

If ionized calcium is high, the condition is not normocalcemic. If kidney function is reduced or vitamin D deficiency remains unresolved, a high PTH cannot yet be assigned confidently to autonomous parathyroid secretion. Because exclusions and repeat testing take time, the normocalcemic label should not be applied from one normal calcium and one high PTH result.

Distinguish inherited low urinary calcium from primary disease#

Familial hypocalciuric hypercalcemia, or FHH, is an inherited change in calcium sensing, and it often produces lifelong mild hypercalcemia, a PTH that is normal or mildly elevated, and relatively low urinary calcium. That combination can look much like primary hyperparathyroidism, but the management implications differ substantially.

The calcium-to-creatinine clearance ratio is often used as a clue, and a ratio below 0.01 raises suspicion for FHH, especially in a younger person or someone with a family history of hypercalcemia. It is not a perfect dividing line. Some people with primary hyperparathyroidism have low ratios, and some people with FHH have values above that threshold. Vitamin D deficiency, reduced kidney function, low calcium intake, and thiazide treatment can lower urine calcium and blur the distinction. Urinary calcium therefore belongs inside a wider inference that includes age, prior calcium results, relatives' results, kidney function, medicines, and, when the probability remains meaningful, testing of relevant calcium-sensing pathway genes. A single ratio should not overrule the rest of the evidence.

Medicines can reveal, mimic, or modify the pattern#

Lithium can shift the calcium-sensing set point and produce hypercalcemia with a nonsuppressed PTH. Thiazide diuretics reduce urinary calcium and can raise serum calcium, sometimes revealing previously unrecognized primary hyperparathyroidism. These associations do not mean that every abnormal result while taking one of these medicines is caused by the medicine.

The diagnostic question is temporal and physiological: what were calcium and PTH before the medicine, what happens across repeat measurements, and does the full pattern persist after an appropriately supervised medication assessment? Abruptly stopping a necessary therapy solely to interpret a laboratory value can create its own harm, so medication review is a coordinated clinical decision rather than a home experiment.

Measure disease burden in bone and kidney#

The term “asymptomatic” can be misleading, because it usually means that a person lacks classic symptoms such as kidney-stone pain or overt skeletal disease, not that the condition has no organ effects. The Fifth Workshop assessment includes kidney function, urinary calcium, renal imaging when indicated, and bone mineral density at the lumbar spine, hip, and distal one-third radius. Vertebral imaging can identify fractures that were not clinically recognized.

These findings serve two purposes. First, they reveal complications that calcium and PTH cannot show. Second, they help determine whether guideline criteria for parathyroid surgery are met. The 2022 framework includes skeletal involvement, kidney involvement, serum calcium more than 1 mg/dL above the laboratory upper limit, or age below 50 years. Kidney criteria include reduced estimated glomerular filtration rate, nephrolithiasis or nephrocalcinosis, and sex-specific thresholds for elevated 24-hour urinary calcium. Exact decisions still depend on the whole patient, operative fitness, preferences, and local expertise.

Imaging answers a later question#

Neck ultrasound, sestamibi scintigraphy, four-dimensional CT, and other localization techniques do not diagnose primary hyperparathyroidism. A visible nodule does not establish autonomous PTH secretion, and a negative scan does not erase a convincing biochemical diagnosis.

Localization is used after a decision for surgery, to help plan the operative approach. That sequence keeps you out of two common errors: calling an incidental neck finding the cause of hypercalcemia, and rejecting a biochemical diagnosis because an abnormal gland was not localized. Diagnosis comes from the physiology. Imaging supports the surgery.

A practical evidence checklist#

When you review a suspected case, look for a traceable chain rather than a label:

• repeated calcium results with albumin and, when relevant, ionized calcium;
• PTH interpreted against the calcium concentration, not only its own reference interval;
• kidney function, phosphate, vitamin D status, and medication context;
• urinary calcium interpreted with its confounders;
• exclusion of secondary causes before using the normocalcemic label;
• bone and kidney assessment for clinically silent involvement;
• localization imaging only after biochemical confirmation and operative planning.